The Promise and Challenges of Gene Therapies
Gene therapies offer transformational benefits to patients, health systems, and society. However, several challenges hinder timely patient access. A report commissioned by Pfizer, penned by Besley et al. (2022), discusses the difficulties of health technology assessment (HTA) of gene therapies and proposes potential solutions.
Gene therapies, as defined by the European Medicines Agency (EMA), are medicines containing genes that lead to therapeutic, prophylactic, or diagnostic effects. They work by inserting ‘recombinant’ genes into the body to treat a variety of diseases, including genetic disorders, cancer, or long-term diseases.
Recommendations for Overcoming HTA Challenges
Based on a review of the literature and insights from an international panel of HTA and health economics experts, the authors propose six overarching recommendations. These recommendations aim to address the challenges in fully capturing the potential value of gene therapies as part of the HTA process and to improve the quality and acceptability of the evidence generated.
The recommendations are not specific to gene therapies and should be consistently applied across HTA of other treatments. However, due to the unique challenges presented by the HTA of gene therapies, if implemented, these recommendations are likely to have a larger impact on the assessment of gene therapies.
The report also assesses the extent to which these recommendations are being achieved in selected European countries, Australia, and Canada. It reviews the HTA outcomes of key gene therapies conducted in these countries to provide further understanding of the current state of play.
💊 International drug price comparison reveal stark price gaps—the U.S. pays 4.2 times more for brand-name drugs than OECD peers.
But are these studies fueling a market collapse or opening a strategic opportunity for sustainable pricing in the U.S. and globally?
Discover the shortcomings of international pricing comparisons and how robust drug pricing analysis can help balance access, affordability, and profitability in a complex market.
#SyenzaNews #healthcare #pricing
🌐 Are you ready to witness a paradigm shift in digital health technology?
The National Institute for Health and Care Excellence (NICE) has announced transformative reforms aimed at accelerating the adoption of digital health innovations within the NHS. By focusing on cost-effectiveness rather than mere cost savings, these changes promise to streamline regulatory processes and enhance evaluations aligned with healthcare priorities.
Dive into this insightful article to explore how NICE’s reforms could reshape the future of healthcare systems globally!
#SyenzaNews #DigitalHealth #HealthEconomics #Innovation
🚀 What could a groundbreaking partnership between BioNTech and Bristol-Myers Squibb mean for the future of solid tumor therapy?
Their collaboration on BNT327 is set to revolutionize immuno-oncology with promising early-phase trial results and a strategic investment of over $1.5 billion. This innovative bispecific antibody targets both PD-L1 and VEGF-A, indicating potential for enhanced patient outcomes in challenging cancers like small cell lung cancer and triple-negative breast cancer.
Curious about how this partnership could reshape cancer treatments? Dive into the full analysis!
#SyenzaNews #oncology #drugdevelopment #MarketAccess
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
